Want to see ACHV full AI Analyst Report?
Achieve Life Sciences (ACHV) Stock Statistics & Valuation Metrics
Total Valuation
Achieve Life Sciences has a market cap or net worth of $702.82M. The enterprise value is $438.27M.
- Market Cap
- $702.82M
- Enterprise Value
- $438.27M
Share Statistics
Achieve Life Sciences has 102,902,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 102,902,490
- Owned by Insiders
- 0.22%
- Owned by Institutions
- 22.32%
Financial Efficiency
Achieve Life Sciences’s return on equity (ROE) is -2.54 and return on invested capital (ROIC) is -150.47%.
- Return on Equity (ROE)
- -2.54
- Return on Assets (ROA)
- -1.31
- Return on Invested Capital (ROIC)
- -150.47%
- Return on Capital Employed (ROCE)
- -1.68
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.95M
- Employee Count
- 28
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Achieve Life Sciences is -4.41. Achieve Life Sciences’s PEG ratio is 0.20.
- PE Ratio
- -4.41
- PS Ratio
- 0.00
- PB Ratio
- -43.52
- Price to FCF
- -14.94
- Price to Operating Cash Flow
- -13.58
- PEG Ratio
- 0.20
Income Statement
In the last 12 months, Achieve Life Sciences had revenue of 0 and earned -54.65M in profits. Earnings per share was -1.25.
- Revenue
- 0
- Gross Profit
- -228.00K
- Operating Income
- -54.88M
- Pretax Income
- -54.65M
- Net Income
- -54.65M
- EBITDA
- -53.60M
- Earnings Per Share (EPS)
- -1.25
Cash Flow
In the last 12 months, operating cash flow was -47.02M and capital expenditures -19,000, giving a free cash flow of -47.04M billion.
- Operating Cash Flow
- -47.02M
- Free Cash Flow
- -47.04M
- Free Cash Flow per Share
- -0.50
Dividends & Yields
Achieve Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.69%
- Earnings Yield
- -17.86%
Stock Price Statistics
- Beta
- 2.63
- 52-Week Price Change
- 30.34%
- 50-Day Moving Average
- 7.49
- 200-Day Moving Average
- 5.63
- Relative Strength Index (RSI)
- 46.41
- Average Volume (3m)
- 1.45M
Important Dates
Achieve Life Sciences upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Achieve Life Sciences as a current ratio of 4.39, with Debt / Equity ratio of 69.50%
- Current Ratio
- 4.39
- Quick Ratio
- 4.39
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- -67.01
Taxes
In the past 12 months, Achieve Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Achieve Life Sciences EV to EBITDA ratio is -5.94, with an EV/FCF ratio of -14.24.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.94
- EV to Free Cash Flow
- -14.24
- EV to Operating Cash Flow
- -14.25
Balance Sheet
Achieve Life Sciences has $187.30M in cash and marketable securities with $14.95M in debt, giving a net cash position of $172.35M billion.
- Cash & Marketable Securities
- $187.30M
- Total Debt
- $14.95M
- Net Cash
- $172.35M
- Net Cash Per Share
- $1.67
- Tangible Book Value Per Share
- -$0.17
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Achieve Life Sciences is $13.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $13.83
- Price Target Upside
- 102.54% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -6.14%
Scores
- Smart Score
- 6
- AI Score
- 47